Skip to main content
. 2018 Mar 16;9(4):421. doi: 10.1038/s41419-018-0459-3

Fig. 7. Human GCT xenograft experiment.

Fig. 7

Inhibition of JNK pathway either pharmacologically with its specific inhibitors (SP600125 and AS601245) or via siRNA resulted in a significant decrease in in vivo growth of GCT cell line (COV434) when xenografted subcutaneously into SCID mice (a, b). In line with these results, histopathological examination showed that there was a marked decrease in cellularity in the tumors with a concomitant decrease in the serum AMH level in the animals after JNK inhibitor treatment was given (c, d)